CBR-5884

Research use only, not for human use.

CBR-5884 is an selective, active of phosphoglycerate dehydrogenase (PHGDH) inhibitor with an IC50 of 33 μM. CBR-5884 inhibits de novo serine synthesis in cancer cells and is selectively toxic to cancer cell lines with high serine biosynthetic activity.

CBR-5884 is an selective, active of phosphoglycerate dehydrogenase (PHGDH) inhibitor with an IC50 of 33 μM. CBR-5884 inhibits de novo serine synthesis in cancer cells and is selectively toxic to cancer cell lines with high serine biosynthetic activity. CBR-5884 selectively inhibits the proliferation of melanoma and breast cancer lines that have a high propensity for serine synthesis. Biochemical characterization of the inhibitor revealed that it was a noncompetitive inhibitor that showed a time-dependent onset of inhibition and disrupted the oligomerization state of PHGDHCBR-5884 (15 or 30 μM; 3-5 days) selectively inhibits breast cancer lines that have a high propensity for serine synthesis. CBR-5884 (15 or 30 μM; 3-5 days) also selectively inhibits the proliferation of melanoma.

CBR-5884 (15 or 30 μM; 3-5 days) selectively inhibits the proliferation of melanoma and breast cancer lines that have a high propensity for serine synthesis. Cell Proliferation Assay Cell Line:Breast and melanoma cell lines Concentration:15 or 30 μM Incubation Time:3-5 days Result:Inhibited the proliferation of melanoma and breast cancer lines.

——

——

Metabolic Enzyme/Protease

Dehydrogenase

PHGDH|serine synthesis

——

——

681159-27-3

336.39

C14H12N2O4S2

>98% (HPLC)

DMSO:47 mg/mL (139.72 mM; Need ultrasonic);H2O:< 0.1 mg/mL (insoluble)

CCOC(=O)c1sc(NC(=O)c2ccco2)c(SC#N)c1C

——

(-20℃)

With Ice Pack

≥ 2 years